Products

Our Products

Eisai Group will promote creating solutions (new drugs) based on scientific evidence in the areas of its expertise: neurology and oncology.

In addition, Eisai is committed to maximizing value for patients by developing additional formulations and expanding indications of our global brands: Halaven®, Lenvima®,  Fycompa® and Dayvigo®.

In the neurology area, our in-house discovered and developed antiepileptic drug Fycompa® is approved as an adjunctive therapy for partial-onset seizures in over 70 countries including Japan, the United States, China and other countries in Europe and in Asia. It is also approved for use as a monotherapy and for adjunctive use in the treatment of partial onset seizures (with or without secondarily generalized seizures) in patients 4 years of age and older in Japan and the United States. In addition, Fycompa is approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries including Japan, the United States, in Europe and in Asia. In addition, we newly launched a global brand product, the insomnia treatment Dayvigo®, in the US in June 2020 and in Japan in July.

In the oncology area, our in-house discovered and developed anticancer agent Halaven has been approved for use in the treatment of breast cancer in over 75 countries and also for use in the treatment of malignant soft tissue sarcoma in over 75 countries. Lenvima, another anticancer agent discovered and developed in-house, has been approved for use in the treatment of thyroid cancer in over 70 countries, including Japan, the United States, in Europe, and in Asia. Additionally, it has been approved as combination therapy with everolimus for use in the treatment of renal cell carcinoma in over 60 countries including the United States and Europe. (In Europe, the brand name for this indication is Kisplyx®.) Lenvima has also been approved for use in the treatment of hepatocellular carcinoma in over 70 countries including in Japan, the United States, China and other countries in Europe and in Asia. Finally, Lenvima has been approved for use in the treatment of endometrial cancer in combination with pembrolizumab in over 10 countries, including the United Statess, Canada and Australia.

(Information current as of May 2021)

Major Products

Sales Regions
Global Brands
Halaven (anticancer agent)
Lenvima (anticancer agent)
Fycompa (antiepileptic agent)

Japan, Americas, Europe, China, Asia
Japan, Americas, Europe, China, Asia
Japan, Americas, Europe, China, Asia
Humira (fully human anti-TNF-α monoclonal antibody) Japan, South Korea

(Information current as of May 2021)

Major Products by Region

JapanPrescription Pharmaceuticals
Humira (fully human anti-TNF-α monoclonal antibody)
Lyrica (pain treatment for neuropathic pain / fibromyalgia)
Lunesta (insomnia treatment)
Methycobal (peripheral neuropathy treatment) 
Lenvima (anticancer agent)
Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)
Halaven (anticancer agent)
Pariet (proton-pump inhibitor)*
Careram (antirheumatic agent)
Elental (branched-chain amino acid preparation)*
Fycompa (antiepileptic agent)
Goofice (chronic constipation treatment)*
Consumer Healthcare (Over-the-Counter) Products
Chocola BB group (including Vitamin B2 preparation Chocola BB Plus)
Americas
Lenvima (anticancer agent)
Banzel (antiepileptic agent)
Halaven (anticancer agent)
Fycompa (antiepileptic agent)
AcipHex (proton-pump inhibitor)
China Lenvima (anticancer agent)
Methycobal (peripheral neuropathy treatment)
Stronger Neo-Minophagen C / Glycyron tablets (liver disease / allergic disease treatment)
Pariet (proton-pump inhibitor)
Aricept (treatment for Alzheimer's disease)
Halaven (anticancer agent)
Fycompa (antiepileptic agent)
Europe Lenvima/Kisplyx (anticancer agent)
Halaven (anticancer agent)
Fycompa (antiepileptic agent)
Zonegran (antiepileptic agent)
Inovelon (antiepileptic agent)
Asia and Latin America Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)
Humira (fully human anti-TNF-α monoclonal antibody)
Lenvima (anticancer agent) 
Pariet (proton-pump inhibitor)
Methycobal (peripheral neuropathy treatment)
Halaven (anticancer agent)
Fycompa (antiepileptic agent)
  • Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan, the Philippines and Thailand.
  • *
    Marketed by EA Pharma.

(Information current as of May 2021)